Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 19, 2021Cancer ScienceOpen Access

Trametinib overcomes KRAS‐G12V–induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR‐mutant lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

KFKoji FukudaAkita UniversitySOSakiko OtaniNational Cancer Center Hospital EastSTShinji TakeuchiTaiyo Yuden (Japan)

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Fukuda et al. (2021) studied this question.

synapsesocial.com/papers/6aa22a3c53a31ffc17d3ce49https://doi.org/10.1111/cas.15035
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Amplification of <i>CRKL</i> Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers2011 · 131 citations
  2. 2MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib2012 · 75 citations
  3. 3Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System2004 · 1,871 citations
  4. 4Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer2014 · 268 citations
  5. 5Targeting Alterations in the RAF–MEK Pathway2019 · 502 citations